Cargando…

Emergence of the G118R Pan-Integrase Resistance Mutation as a Result of Low Compliance to a Dolutegravir-Based cART

HIV-1 resistance towards integrase inhibitors is a potential threat of the success of HIV-1 combination treatment. G118R is a rare drug resistance mutation conferring pan-integrase resistance. Here, we describe the occurrence of G118R in a HIV-1 subtype-B-positive individual with major compliance pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mens, Helene, Fjordside, Lasse, Fonager, Jannik, Gerstoft, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9326666/ https://www.ncbi.nlm.nih.gov/pubmed/35893472 http://dx.doi.org/10.3390/idr14040053

Ejemplares similares

Using (18)F-FDG PET/CT to rule out Richter transformation as cause of deterioration in a patient with chronic lymphatic leukemia and severe COVID-19: A case report
por: Fjordside, Lasse, et al.
Publicado: (2021)

Neurological Response to cART vs. cART plus Integrase Inhibitor and CCR5 Antagonist Initiated during Acute HIV
por: Valcour, Victor G., et al.
Publicado: (2015)

Probing Resistance Mutations in Retroviral Integrases by Direct Measurement of Dolutegravir Fluorescence
por: Thierry, Eloïse, et al.
Publicado: (2017)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
por: Ziegler, Robert E., et al.
Publicado: (2018)

Biochemical activity of RAGs is impeded by Dolutegravir, an HIV integrase inhibitor
por: Nilavar, Namrata M., et al.
Publicado: (2020)

Complete manuscript Title: Changes in RANKL during the first two years after cART initiation in HIV-infected cART naïve adults
por: Mathiesen, Inger Hee, et al.
Publicado: (2017)

Improved induced innate immune response after cART initiation in people with HIV
por: Hove-Skovsgaard, Malene, et al.
Publicado: (2022)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

Emergent dolutegravir resistance in integrase-naïve, treatment experienced patients from Zimbabwe
por: Mandikiyana Chirimuta, Linda A., et al.
Publicado: (2022)

Combined cART including Tenofovir Disoproxil, Emtricitabine, and Dolutegravir has potent therapeutic effects in HIV-1 infected humanized mice
por: Weichseldorfer, Matthew, et al.
Publicado: (2021)

The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
por: Wainberg, Mark, et al.
Publicado: (2014)

Treatment Emergent Dolutegravir Resistance Mutations in Individuals Naïve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review
por: Tao, Kaiming, et al.
Publicado: (2023)

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir
por: Song, Ivy, et al.
Publicado: (2014)

In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2
por: Smith, Robert A, et al.
Publicado: (2015)

The site-specific integration reaction of Listeria phage A118 integrase, a serine recombinase
por: Mandali, Sridhar, et al.
Publicado: (2013)

Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding
por: Chitongo, Rumbidzai, et al.
Publicado: (2020)

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: A systematic review and meta-analysis
por: Ngoufack Jagni Semengue, Ezechiel, et al.
Publicado: (2022)

Dolutegravir Interactions with HIV-1 Integrase-DNA: Structural Rationale for Drug Resistance and Dissociation Kinetics
por: DeAnda, Felix, et al.
Publicado: (2013)

Effect of aprepitant on kynurenine to tryptophan ratio in cART treated and cART naïve adults living with HIV
por: Spitsin, Sergei, et al.
Publicado: (2021)

Correction: Molecular dynamic simulations to investigate the structural impact of known drug resistance mutations on HIV-1C Integrase-Dolutegravir binding
por: Chitongo, Rumbidzai, et al.
Publicado: (2020)

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol
por: Semengue, Ezechiel Ngoufack Jagni, et al.
Publicado: (2020)

Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model
por: Galli, Andrea, et al.
Publicado: (2018)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
por: Gil, Horacio, et al.
Publicado: (2022)

Evaluation of Circulating and Archived HIV-1 Integrase Drug-Resistance Variants among Patients on Third-Line ART in Cameroon: Implications for Dolutegravir-Containing Regimens in Resource-Limited Settings
por: Fokam, Joseph, et al.
Publicado: (2022)

How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir
por: Das, Atze T., et al.
Publicado: (2018)

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
por: Vavro, Cindy, et al.
Publicado: (2022)

Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?
por: Krastinova, Evguenia, et al.
Publicado: (2015)

Association between obesity and combination antiretroviral therapy (cART) adherence among persons with early-stage HIV infection initiating cART
por: Musinguzi, Nicholas, et al.
Publicado: (2021)

Letter to the editor: A norovirus intervariant GII.4 recombinant in Victoria, Australia, June 2016: the next epidemic variant? Reflections and a note of caution
por: Fonager, Jannik, et al.
Publicado: (2016)

Neurofilament Light in Cerebrospinal Fluid is Associated With Disease Staging in European Lyme Neuroborreliosis
por: Mens, Helene, et al.
Publicado: (2022)

Absence of Resistance Mutations in the Integrase Coding Region among ART-Experienced Patients in the Republic of the Congo
por: Got, Ferdinand Emaniel Brel, et al.
Publicado: (2021)

Disseminated toxoplasmosis in an HIV positive patient in cART era
por: Cambrea, Simona Claudia, et al.
Publicado: (2014)

Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART
por: Derache, Anne, et al.
Publicado: (2019)

Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort
por: Abdullahi, Adam, et al.
Publicado: (2023)

Emergence of Resistance to Integrase Strand Transfer Inhibitors during Dolutegravir Containing Triple-Therapy in a Treatment-Experienced Patient with Pre-Existing M184V/I Mutation
por: Braun, Dominique L., et al.
Publicado: (2020)

Antiviral activity of dolutegravir in subjects with failure on an integrase inhibitor-based regimen: week 24 phase 3 results from VIKING-3
por: Nichols, G, et al.
Publicado: (2012)

Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
por: Demarest, James, et al.
Publicado: (2018)

Resistance in Patients Failing Integrase Strand Transfer Inhibitors: A Call to Replace Raltegravir With Dolutegravir in Third-Line Treatment in South Africa
por: Steegen, Kim, et al.
Publicado: (2019)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qjans7l05c2m9p1cpmbo6qn92t